Dr. Lee, Principal Investigator of the Core A subcontract at University of Virginia, will communicate with Drs. Chung and Petros, Co-Directors of the Administrative and Services Core A at Emory University, to archive data generated from the program projects, which will be stored at the central database system located in the Urology Department at Emory University and Health System. Analyses of the data will be conducted at both Emory University and the University of Virginia based on an advanced statistical computing environment, including S-PLUS, an object-oriented statistical software (Insightful, Inc.;Seattle, WA) and other programming software. The Emory University School of Public Health and the Department of Health Evaluation Sciences at the University of Virginia have their own NT server with 72 gigabytes of Redundant Array Disk space and 1 gigabyte of RAM. An UltraSpard with 1 gigabyte of RAM and S+ and SAS is available to department members for CPU-intensive computations. The analysis results and reports will be provided to Project Directors and stored at the central database at Emory. Dr. Lee will provide biostatistical and bioinformatics support, including experimental designs and data analysis, as described in the Aims of each research project and microarray and tissue array to seek for genes differentially expressed in the cell culture/animal models and in clinical specimens. Dr. Lee, a long-term collaborator and an experienced biostatistician and the director of microarray/GeneChip facility at the University of Virginia, and Dr. Robert Lyles, an experienced biostatistician from Emory University School of Public Health will consult and collaborate on projects that need their input.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA098912-09
Application #
8382411
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
9
Fiscal Year
2012
Total Cost
$141,619
Indirect Cost
$42,392
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Farach-Carson, Mary C; Lin, Sue-Hwa; Nalty, Theresa et al. (2017) Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow? Front Oncol 7:163
Stewart, Paul A; Khamis, Zahraa I; Zhau, Haiyen E et al. (2017) Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer. Oncotarget 8:39209-39217
Masko, Elizabeth M; Alfaqih, Mahmoud A; Solomon, Keith R et al. (2017) Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Prostate 77:446-457
Jolly, Mohit Kumar; Boareto, Marcelo; Debeb, Bisrat G et al. (2017) Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer 3:21
Alfaqih, Mahmoud A; Allott, Emma H; Hamilton, Robert J et al. (2017) The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol 14:107-119
Guan, Yang; Zhang, Yi; Xiao, Li et al. (2017) Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye. Mol Pharm 14:1-13
Nandana, Srinivas; Tripathi, Manisha; Duan, Peng et al. (2017) Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. Cancer Res 77:1331-1344
Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727
Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2017) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat :1-13
Tighiouart, Mourad; Li, Quanlin; Rogatko, André (2017) A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials. Stat Med 36:280-290

Showing the most recent 10 out of 208 publications